NNP
GILD icon

Nachman Norwood & Parrott’s Gilead Sciences GILD Stock Holding History

Nachman Norwood & Parrott’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,813
Closed -$115K – 556
2020
Q3 		$115K Buy
+1,813
New +$126K 0.02% 314

Other funds holding GILD

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nachman Norwood & Parrott's GILD Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of Gilead Sciences (GILD) in Q4 2020, closing a stake of 1,813 shares — an estimated $115K sold.

Nachman Norwood & Parrott first reported a position in GILD in Q3 2020 and held it in 1 quarter. The position peaked at $115K in Q3 2020. 1,564 funds tracked by Wall St. Rank hold GILD as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining Gilead Sciences position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 1,813 Gilead Sciences shares in Q4 2020, an estimated $115K.
  • Nachman Norwood & Parrott first reported a position in Gilead Sciences in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's Gilead Sciences position peaked at $115K in Q3 2020.
  • 1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.